MYD88 and systemic lupus erythematosus: This was demonstratedin a study on RAW264.7 murine macrophages, in which DHA reduced LPS-inducedinflammation by selectively targeting the TRIF/IRF3 signaling andleaving the MyD88 pathway unaffected. This can lead to targeted therapy in which partial inflammationreduction without complete abolishment is desirable, such as in autoimmunediseases (e.g., rheumatoid arthritis or other autoimmune rheumaticdiseases, such as systemic lupus erythematosus, SLE).